June 8, 2015 - The Center for Biomedical Research (CBR) is partnering with the Ackerman Cancer Center as part of a clinical meta-registry for clinical outcomes and long-term follow-up of cancer patients receiving proton therapy.
Ackerman has joined the registry study developed and managed by the CBR in collaboration with the Provision Center for Proton Therapy. The registry study meets all guidelines as outlined in the Agency for Healthcare Research and Quality's (AHRQ) guidelines for Registries for Evaluating Patient Outcomes.
"With the PRO 0425 study, we are collecting data that will allow us to compare information across disease sites and treatment modalities and provide a unique window into the long-term effectiveness of proton therapy," said Marcio Fagundes, M.D., medical director for Provision Center for Proton Therapy and principal investigator.
Located in Jacksonville, Fla., Ackerman is the first private, physician-owned practice to offer proton therapy. The center began treating patients in late April.
The Center for Biomedical Research (CBR) specializes in the management of clinical trials and has a lengthy history of managing groundbreaking clinical trials such as Herceptin, Avastin and most recently Imbruvica, of which CBR was the only clinical research site in the Southeastern United States. The Center for Biomedical Research has managed hundreds of clinical trials with a particular focus on medical oncology, proton therapy and positron emission tomography (PET) imaging. CBR is regionally noted for its expertise in conducting pharmaceutical trials targeting smaller, rare cancers with specific tumor mutations.
For more information: www.biomed-research.com
